Kimia Biosciences
32.40
-1.60(-4.71%)
Market Cap₹153.33 Cr
PE Ratio19.65
IndustryHealthcare
Company Performance:
1D-4.71%
1M+11.72%
6M-54.47%
1Y-27.71%
5Y-46.31%
View Company Insightsright
More news about Kimia Biosciences
16Aug 25
Kimia Biosciences Reports Mixed Q1 FY2026 Results with Sequential Growth
Kimia Biosciences Limited released unaudited standalone financial results for Q1 FY2026 ended June 30, 2025. Total income was ₹6,103.00 lakhs (-1.61% YoY, +20.18% QoQ), net profit ₹613.00 lakhs (-1.13% YoY, +6.06% QoQ), and EPS ₹4.31 (-2.05% YoY, +6.42% QoQ). The company showed resilience with significant sequential growth despite slight year-over-year declines. Results were published in English and Hindi newspapers for regulatory compliance.
14Aug 25
Kimia Biosciences Approves Q1 Results, Appoints New CFO, and Raises ₹2 Crore Loan
Kimia Biosciences announced Q1 FY2024 results with revenue growth of 5.29% but a 57.97% decrease in profit. The company appointed Mr. Pradip Kumar Sharma as the new CFO and approved an unsecured loan of ₹2 crores at 8% interest. The Board also addressed a BSE warning letter regarding compliance with SEBI regulations on annual report submission.
Kimia Biosciences
32.40
-1.60
(-4.71%)
1 Year Returns:-27.71%
Industry Peers
Sun Pharmaceutical
1,782.60
(+1.27%)
Divis Laboratories
6,642.50
(0.0%)
Torrent Pharmaceuticals
4,092.20
(+3.95%)
Cipla
1,467.90
(-4.11%)
Dr Reddys Laboratories
1,242.80
(-1.07%)
Lupin
2,214.30
(+3.01%)
Mankind Pharma
2,311.80
(+3.17%)
Zydus Life Science
927.55
(-0.38%)
Aurobindo Pharma
1,235.40
(+0.33%)
Alkem Laboratories
5,806.50
(+2.67%)